Toshifusa Nakajima Selected Research

Irinotecan (Camptosar)

11/2013	FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
5/2004	A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshifusa Nakajima Research Topics

Disease

17	Stomach Neoplasms (Stomach Cancer) 05/2018 - 01/2002
10	Neoplasms (Cancer) 01/2017 - 01/2002
4	Colorectal Neoplasms (Colorectal Cancer) 01/2017 - 11/2013
4	Neutropenia 01/2015 - 01/2004
3	Rectal Neoplasms (Rectal Cancer) 01/2019 - 01/2015
3	Carcinoma (Carcinomatosis) 01/2019 - 06/2013
2	Diarrhea 05/2004 - 01/2004
1	Vomiting 05/2018
1	Cicatrix (Scar) 06/2013
1	Adenocarcinoma 06/2013
1	Adenoma (Adenomas) 06/2013
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2012
1	Overweight 12/2009
1	Neoplasm Metastasis (Metastasis) 05/2009
1	Lymphatic Metastasis 05/2004
1	Nausea 01/2004
1	Stomatitis 01/2004
1	Leukopenia 01/2004
1	Anorexia 01/2004
1	Fatigue 01/2004
1	Liver Cirrhosis (Hepatic Cirrhosis) 11/2002

Drug/Important Bio-Agent (IBA)

6	Fluorouracil (Carac)FDA LinkGeneric 09/2014 - 06/2003
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2019 - 09/2014
5	Cisplatin (Platino)FDA LinkGeneric 05/2018 - 05/2004
3	Cetuximab (Erbitux)FDA Link 01/2017 - 01/2016
2	Trastuzumab (Herceptin)FDA Link 05/2018 - 01/2018
2	S-1 plus cisplatinIBA 05/2018 - 02/2014
2	Leucovorin (Folinic Acid)FDA Link 09/2014 - 11/2013
2	Irinotecan (Camptosar)FDA LinkGeneric 11/2013 - 05/2004
1	ErbB Receptors (EGF Receptor)IBA 01/2016
1	EpiregulinIBA 01/2016
1	AmphiregulinIBA 01/2016
1	LigandsIBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Capecitabine (Xeloda)FDA Link 09/2014
1	Drug CombinationsIBA 09/2014
1	Epirubicin (Ellence)FDA LinkGeneric 09/2014
1	PlatinumIBA 02/2014
1	Platinum Compounds (Compounds, Platinum)IBA 02/2014
1	Docetaxel (Taxotere)FDA Link 02/2014
1	Bevacizumab (Avastin)FDA Link 11/2013
1	titanium silicide (TS-1)IBA 10/2013
1	S 1 (combination)IBA 05/2012
1	Gemcitabine FDA Link 05/2012
1	Proteins (Proteins, Gene)FDA Link 04/2011
1	Pepsinogen A (Pepsinogen)IBA 04/2011
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 04/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2011
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2011
1	tegafur-gimeracil-oteracilIBA 01/2004
1	BilirubinIBA 01/2004
1	PotassiumIBA 01/2004
1	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2003
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 06/2003
1	Asialoglycoprotein ReceptorIBA 11/2002

Therapy/Procedure

10	Adjuvant Chemotherapy 04/2016 - 01/2002
7	Drug Therapy (Chemotherapy) 01/2017 - 06/2003
6	Gastrectomy 06/2013 - 01/2004
5	Lymph Node Excision (Lymph Node Dissection) 11/2011 - 01/2002
4	Chemoradiotherapy 01/2019 - 09/2014
4	Therapeutics 10/2013 - 05/2004
1	FPEPIR regimen 09/2014
1	Radiotherapy 09/2014
1	Operative Surgical Procedures 12/2009